

# Benjamin C Lewis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4174353/publications.pdf>

Version: 2024-02-01

26  
papers

972  
citations

471061

17  
h-index

580395

25  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1289  
citing authors

#	ARTICLE	IF	CITATIONS
1	The glycosidation of xenobiotics and endogenous compounds: Versatility and redundancy in the UDP glucosyltransferase superfamily. , 2012, 134, 200-218.		104
2	Mechanism-Based Inactivation of Human Cytochrome P450C8 by Drugs in Vitro. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 996-1007.	1.3	90
3	Influence of mutations associated with Gilbert and Criglerâ€Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenetics and Genomics, 2007, 17, 1017-1029.	0.7	86
4	Electrochemical characterisation of the human cytochrome P450 CYP2C9. Biochemical Pharmacology, 2005, 69, 1533-1541.	2.0	72
5	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. British Journal of Clinical Pharmacology, 2006, 61, 570-584.	1.1	66
6	MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1. Scientific Reports, 2017, 7, 13996.	1.6	62
7	Morphine Glucuronidation and Glucosidation Represent Complementary Metabolic Pathways That Are Both Catalyzed by UDP-Glucuronosyltransferase 2B7: Kinetic, Inhibition, and Molecular Modeling Studies. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 126-137.	1.3	55
8	Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. British Journal of Clinical Pharmacology, 2007, 64, 450-457.	1.1	51
9	Critical Roles of Residues 36 and 40 in the Phenol and Tertiary Amine Aglycone Substrate Selectivities of UDP-Glucuronosyltransferases 1A3 and 1A4. Molecular Pharmacology, 2007, 72, 1054-1062.	1.0	50
10	Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochemical Pharmacology, 2007, 73, 1463-1473.	2.0	43
11	Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance. Scientific Reports, 2018, 8, 3697.	1.6	38
12	Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis. Archives of Biochemistry and Biophysics, 2007, 468, 58-69.	1.4	31
13	Creation of a yeast artificial chromosome fragmentation vector based on lysine-2. Genetic Analysis, Techniques and Applications, 1992, 9, 86-90.	1.5	30
14	Identification of Residues That Confer Sugar Selectivity to UDP-Glycosyltransferase 3A (UGT3A) Enzymes. Journal of Biological Chemistry, 2012, 287, 24122-24130.	1.6	28
15	Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development. Molecules, 2016, 21, 615.	1.7	27
16	Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling. Biochemical Pharmacology, 2011, 82, 2016-2023.	2.0	25
17	Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochemical Pharmacology, 2012, 84, 1511-1521.	2.0	23
18	Arginine analogues incorporating carboxylate bioisosteric functions are micromolar inhibitors of human recombinant DDAH-1. Organic and Biomolecular Chemistry, 2015, 13, 11315-11330.	1.5	18

#	ARTICLE	IF	CITATIONS
19	AFM study of the interaction of cytochrome P450 2C9 with phospholipid bilayers. <i>Chemistry and Physics of Lipids</i> , 2010, 163, 182-189.	1.5	17
20	Application of Homology Modeling to Generate CYP1A1 Mutants with Enhanced Activation of the Cancer Chemotherapeutic Prodrug Dacarbazine. <i>Molecular Pharmacology</i> , 2011, 80, 879-888.	1.0	16
21	Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. <i>Scientific Reports</i> , 2017, 7, 2871.	1.6	15
22	Warfarin resistance associated with genetic polymorphism of VKORC1. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 44-50.	0.7	13
23	Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 453-461.	0.7	5
24	Drug and Chemical Glucosidation by Control Supersomes and Membranes from <i>Spodoptera frugiperda</i> (Sf) 9 Cells: Implications for the Apparent Glucuronidation of Xenobiotics by UDP-glucuronosyltransferase 1A5. <i>Drug Metabolism and Disposition</i> , 2019, 47, 271-278.	1.7	3
25	Generation, Validation, and Application of a P450 Homology Model. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 2233-2240.	1.0	3
26	Omental Infarction Mimicking Cholecystitis. <i>Case Reports in Surgery</i> , 2015, 2015, 1-3.	0.2	1